Production and Characterization of Recombinant Antibody Variants Neutralizing SARS-CoV-2

Autor: Iakubovskaia, Alina

Coronaviruses are ssRNA viruses, some of which can infect human lung epithelium via binding the ACE2 receptor. The outbreak of the severe acute respiratory syndrome corona-virus-2 (SARS-CoV-2) reported at the end of 2019 has forced the biomedical fie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______4853::1b091603c55245235f11e56b996d53e0
https://trepo.tuni.fi/handle/10024/139558

Neutralizing antibodies after the third COVID-19 vaccination in healthcare workers with or without breakthrough infection.

Autor: Reinholm A; Institute of Biomedicine, University of Turku, Turku, Finland. arttu.j.reinholm@utu.fi., Maljanen S; Institute of Biomedicine, University of Turku, Turku, Finland., Jalkanen P; Institute of Biomedicine, University of Turku, Turku, Finland., Altan E; Institute of Biomedicine, University of Turku, Turku, Finland., Tauriainen S; Institute of Biomedicine, University of Turku, Turku, Finland., Belik M; Institute of Biomedicine, University of Turku, Turku, Finland., Skön M; Finnish Institute for Health and Welfare, Helsinki, Finland., Haveri A; Finnish Institute for Health and Welfare, Helsinki, Finland., Österlund P; Finnish Institute for Health and Welfare, Helsinki, Finland., Iakubovskaia A; Department of Physiology, Medicum, University of Helsinki, Helsinki, Finland., Pasternack A; Department of Physiology, Medicum, University of Helsinki, Helsinki, Finland., Naves RA; Department of Physiology, Medicum, University of Helsinki, Helsinki, Finland., Ritvos O; Department of Physiology, Medicum, University of Helsinki, Helsinki, Finland., Miettinen S; Department of Infectious Diseases, Meilahti Vaccination Research Center, MeVac, Helsinki, University Hospital and University of Helsinki, Helsinki, Finland., K Häkkinen H; Department of Virology, University of Helsinki, Helsinki, Finland., Ivaska L; Department of Paediatrics and Adolescent Medicine, Turku University Hospital and University of Turku, Turku, Finland.; InFlames Research Flagship Center, University of Turku, Turku, Finland., Tähtinen PA; Department of Paediatrics and Adolescent Medicine, Turku University Hospital and University of Turku, Turku, Finland., Lempainen J; Institute of Biomedicine, University of Turku, Turku, Finland.; Department of Paediatrics and Adolescent Medicine, Turku University Hospital and University of Turku, Turku, Finland.; Clinical Microbiology, Turku University Hospital, Turku, Finland., Kantele A; Department of Infectious Diseases, Meilahti Vaccination Research Center, MeVac, Helsinki, University Hospital and University of Helsinki, Helsinki, Finland., Kakkola L; Institute of Biomedicine, University of Turku, Turku, Finland.; InFlames Research Flagship Center, University of Turku, Turku, Finland.; Clinical Microbiology, Turku University Hospital, Turku, Finland., Julkunen I; Institute of Biomedicine, University of Turku, Turku, Finland.; InFlames Research Flagship Center, University of Turku, Turku, Finland.; Clinical Microbiology, Turku University Hospital, Turku, Finland., Kolehmainen P; Institute of Biomedicine, University of Turku, Turku, Finland. pekka.j.kolehmainen@utu.fi.

Publikováno v: Communications medicine [Commun Med (Lond)] 2024 Feb 23; Vol. 4 (1), pp. 28. Date of Electronic Publication: 2024 Feb 23.